However, the absence of E61-CAR- T cell effects in vivo suggests that previous CAR constructs used to target B7-H3 might be more effective than E61-CAR.4,5 Because B7-H3 expressed in pericytes and myeloid cells47 might cause on-target off-tumor side effects, care is needed in clinical trials of CAR-T cells targeting B7-H3. Here, CD276 is linked to neoplasm.